From: Risk factors affecting outcome of rhino-orbital-cerebral mucormycosis in COVID-19 patients
 | No death | Death | Test value | p-value | Sig. |
---|---|---|---|---|---|
No. = 24 | No. = 9 | ||||
Interval from symptom onset to treatment | |||||
 Median (IQR) | 8 (5–12) | 5 (3–7) | −1.524b | 0.127 | NS |
 Range | 2–63 | 1–14 | |||
Endoscopic treatment | 19 (79.2%) | 5 (55.6%) | 1.840a | 0.175 | NS |
Combined (endoscopic and external) | 4 (16.7%) | 3 (33.3%) | 1.088a | 0.297 | NS |
External | 2 (8.3%) | 0 (0.0%) | 0.798a | 0.372 | NS |
Total no. of surgical procedures | |||||
 0 | 1 (4.8%) | 1 (14.3%) | 4.000a | 0.261 | NS |
 1 | 12 (57.1%) | 6 (85.7%) | |||
 2 | 7 (33.3%) | 0 (0.0%) | |||
 3 | 1 (4.8%) | 0 (0.0%) | |||
Inf. turb. | 23 (95.8%) | 9 (100.0%) | 0.387a | 0.534 | NS |
Middle turb. | 22 (91.7%) | 9 (100.0%) | 0.798a | 0.372 | NS |
MMA | 23 (95.8%) | 9 (100.0%) | 0.387a | 0.534 | NS |
Septectomy | 11 (45.8%) | 6 (66.7%) | 1.137a | 0.286 | NS |
Palatal debrid. | 2 (8.3%) | 1 (11.1%) | 0.061a | 0.805 | NS |
Ethmoidectomy | 22 (91.7%) | 9 (100.0%) | 0.798a | 0.372 | NS |
Sphenoidotomy | 20 (83.3%) | 5 (55.6%) | 2.750a | 0.097 | NS |